Business Context and Reporting Period
Kiora Pharmaceuticals, Inc. (KPRX) filed this Form 8-K on June 6, 2024, reporting a material modification to the rights of security holders. The filing details the implementation of a 1-for-9 reverse stock split of the Company's common stock, approved by stockholders on May 1, 2024, and filed with the Delaware Secretary of State on June 6, 2024.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on capital structure adjustments.
| Metric | Pre-Split | Post-Split (Approx.) |
|---|---|---|
| Common Shares Outstanding | 26,735,116 | 2,970,568 |
| Warrants Outstanding | 67,136,173 | 7,459,575 |
| Fully Diluted Shares | 100,056,883 | 11,117,431 |
Material Changes
- Reverse Stock Split: A 1-for-9 reverse split was effected to comply with Nasdaq Capital Market minimum bid price requirements. The effective time was 12:01 a.m. Eastern Time on June 11, 2024.
- Fractional Shares: No fractional shares were issued; holders received cash in lieu of fractions based on the closing price on June 10, 2024.
- Adjustments: Proportional adjustments were made to outstanding stock options, warrants, and shares reserved under the equity incentive plan.
- Warrant Expirations: Class D warrants for 3,427,479 shares expired on June 6, 2024, prior to the split adjustment.
Guidance, Outlook, and Risks
The Company expects the reverse stock split-adjusted shares to begin trading on the Nasdaq Capital Market at the open on June 11, 2024, under the new CUSIP number 49721T 507. The trading symbol "KPRX" remains unchanged. The filing does not provide specific financial guidance, management commentary on future operations, or new risk factors beyond the context of maintaining the Nasdaq listing.
Investor Verification Checklist
- Verify the new CUSIP number (49721T 507) for trading purposes starting June 11, 2024.
- Confirm the cash payment received for any fractional shares based on the June 10, 2024 closing price.
- Review the adjusted exercise prices and share counts for any held stock options or warrants.
- Monitor the stock price to ensure compliance with Nasdaq minimum bid price requirements post-split.